Investor Letter Highlights Potential of Crinetics Pharmaceuticals (CRNX) in Biotech Sector

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter, reporting the S&P 1500 Health Care Index returned 5.5% while the S&P 500 saw a -4.3% return. The fund underperformed due to stock selection in biotechnology and pharmaceuticals. Top five holdings are available for review in the letter.

In the same letter, PGIM Jennison Health Sciences Fund highlighted Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage pharmaceutical company. Shares of CRNX lost 39.75% of their value over 52 weeks, closing at $29.06 per share on July 7, 2025. Crinetics focuses on developing oral small molecules for endocrine indications.

Crinetics Pharmaceuticals, Inc. (CRNX) has a Prescription Drug User Act (PDUFA) date set for 9/25/25, with lead asset Paltusotine in development for acromegaly and carcinoid syndrome. The company’s second asset, Atumelnant, is in development for Congenital Adrenal Hyperplasia (CAH) and Cushing’s Disease. Analysts are discussing the potential of CRNX as an investment and comparing it to AI stocks.

Investor letters from hedge funds and leading investors discuss the potential of CRNX as an investment, citing AI stocks for greater upside potential. While CRNX is promising, AI stocks are believed to offer higher returns within a shorter timeframe. Analysts suggest exploring undervalued AI stocks for significant gains.

For more insights, readers can check out articles covering the best and worst Dow stocks for the next 12 months and unstoppable stocks that could double their money. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Should You Hold Crinetics Pharmaceuticals (CRNX)?